5187 completed. 5187 Phase 2, 876 Phase 1, 513 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5187 | Completed 5187 |
| Phase 1 | 876 | Completed 876 |
| Phase 3 | 513 | Completed 513 |
Follow Nervous System Diseases: new trials by email Literature Review of Nervous System Diseases trials Research Report on Nervous System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intranasal Insulin to Prevent Intensive Care Unit Delirium Intranasal insulin-40U, Intranasal sodium chloride 0.9% - Delirium - Postoperative | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 30 | 2026-04-30 | 2026-08-03 |
| Acute Nicotine Gum and Tinnitus Loudness in Non-Smoking Adults Nicotine polacrilex gum 4 mg, Placebo gum - Tinnitus, Chronic Subjective Tinnitus | Phase 1 / Phase 2 | Completed | San Diego State University | 29 | 2026-03-25 | 2026-10-16 |
| Effect of Dexmedetomidine Dosage on Postoperative Delirium in Geriatric Orthopedic Surgery Dexmedetomidine (Low dose), Dexmedetomidine (High dose), Fentanyl - Delirium - Postoperative | Phase 2 | Completed | Benha University | 75 | 2026-02-26 | 2026-08-25 |
| Fisetin in Mild Alzheimer's Disease Fisetin - Alzheimer s Disease, Alzheimer Dementia | Phase 2 | Completed | Sunnybrook Health Sciences Centre | 5 | 2026-01-27 | 2026-08-20 |
| A Randomized Comparison Between 0.67 mcg/kg, 1 mcg/kg, and 1.33 mcg/kg of Perineural Dexmedetomidine for Ultrasound-Guided Infraclavicular Block dexmedetomidine (perineural) 0.67 mcg/kg, dexmedetomidine (perineural) 1 mcg/kg, dexmedetomidine (perineural) 1.33 mcg/kg - Analgesia, Pain, Acute | Phase 2 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 69 | 2025-12-28 | 2026-07-07 |
| Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain Intravenous oxytocin, Intravenous placebo, Intranasal oxytocin - Pain, Acute | Phase 2 | Completed | Wake Forest University Health Sciences | 24 | 2025-11-05 | 2026-06-30 |
| Fentanyl Versus Hydromorphone in Patients on Mechanical Ventilation fentanyl, Hydromorphone - Mechanical Ventilation, Sedation and Analgesia | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 319 | 2025-11-03 | 2026-07-14 |
| HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. HRS-7450 Injection, HRS-7450 Injection Placebo - Acute Ischemic Stroke | Phase 2 | Completed | Fujian Shengdi Pharmaceutical Co., Ltd. | 210 | 2025-10-31 | 2026-10-20 |
| Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke Ivolumab 420mg (three vials) - Acute Stroke | Phase 2 | Completed | The Affiliated Hospital of Xuzhou Medical University | 132 | 2025-10-30 | 2026-09-10 |
| Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine) A-DOPAMINE - Parkinson Disease | Phase 1 / Phase 2 | Completed | University Hospital, Lille | 1 | 2025-10-01 | 2026-05-22 |
| Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone Risperidone 4mg/day, Ashwagandha, Placebo - Schizophrenia Patients, Neuroinflammation | Phase 2 | Completed | Hasanuddin University | 80 | 2025-10-01 | 2026-05-12 |
| A Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances RE03, Placebo - Posttraumatic Stress Disorder (PTSD), Sleep Disturbances and Insomnia | Phase 2 | Completed | Reconnect Labs | 12 | 2025-09-30 | 2026-07-23 |
| A Clinical Trial of MT200605 for the Treatment of Acute Ischemic Stroke MT200605, Placebo - Acute Ischemic Stroke | Phase 2 | Completed | Shaanxi Micot Pharmaceutical Technology Co., Ltd. | 360 | 2025-09-30 | 2026-11-05 |
| Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME) aspirin + clopidogrel, Aspirin - Acute Ischemic Stroke | Phase 2 | Completed | University of Alberta | 3 | 2025-09-02 | 2026-09-28 |
| Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime) aspirin + clopidogrel, Aspirin - Acute Ischemic Stroke | Phase 2 | Completed | University of Alberta | 3 | 2025-09-02 | 2026-07-16 |
| Virtual Reality for Pain and Anxiety Relief During Peripheral Angioplasty Virtual Reality, dexketoprofen + midazolam - Peripheral Angioplasty, Pain Management | Phase 2 / Phase 3 | Completed | Kastamonu University | 52 | 2025-08-01 | 2025-11-19 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder RAP-219, Placebo - Bipolar 1 Disorder | Phase 2 | Completed | Rapport Therapeutics Inc. | 253 | 2025-07-25 | 2026-10-26 |
| A Phase 2 Study of JNT-517 in Adolescent Participants With Phenylketonuria JNT-517 Tablet, Placebo - Phenylketonuria (PKU) | Phase 2 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 14 | 2025-07-16 | 2026-05-13 |
| Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride New TETA 4HCl Formulation, Standard of Care - Wilson's Disease | Phase 2 | Completed | Orphalan | 10 | 2025-07-15 | 2026-04-06 |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia Placebo, ML-007C-MA BID, ML-007C-MA QD - Schizophrenia | Phase 2 | Completed | MapLight Therapeutics | 307 | 2025-06-27 | 2026-07-09 |
Showing 20 of 5187. Sign in to see all of them.
Alzheimer Disease (414) · Brain Neoplasms (373) · Parkinson Disease (362) · Stroke (312) · Glioblastoma (230) · Multiple Sclerosis (214) · Central Nervous System Neoplasms (202) · Gliosarcoma (158) · Ischemic Stroke (151) · Amyotrophic Lateral Sclerosis (149) · Pain (146) · Glioma (135) · Epilepsy (131) · Agnosia (130) · Dementia (128)
Central Nervous System Diseases (3036) · Brain Diseases (2592) · Pathological Conditions, Signs and Symptoms (1739) · Signs and Symptoms (1328) · Neurologic Manifestations (1305) · Neurodegenerative Diseases (1257) · Mental Disorders (1011) · Neuromuscular Diseases (895) · Neoplasms (714) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (688) · Cardiovascular Diseases (650) · Genetic Diseases, Inborn (641) · Vascular Diseases (641) · Neoplasms by Site (637)
Temozolomide (93) · Radiotherapy (75) · Saline Solution (74) · Sodium Chloride (74) · Bevacizumab (61) · Cyclophosphamide (34) · Sugars (34) · Donepezil (31) · Botulinum Toxins, Type A (30) · Filgrastim (30) · Levetiracetam (30) · Melatonin (30) · Transcranial Direct Current Stimulation (30) · Irinotecan (28) · Carboplatin (27)
National Cancer Institute (NCI) (82) · National Institute of Neurological Disorders and Stroke (NINDS) (79) · Novartis Pharmaceuticals (61) · GlaxoSmithKline (60) · Duke University (57) · Pfizer (53) · US Department of Veterans Affairs (48) · VA Office of Research and Development (41) · Johns Hopkins University (34) · Biogen (33) · Eli Lilly and Company (32) · Assistance Publique - Hôpitaux de Paris (31) · UCB Pharma (31) · Sanofi (30) · Brigham and Women's Hospital (29)
United States (3037) · Canada (492) · Germany (460) · France (444) · United Kingdom (429) · Spain (343) · Italy (305) · Australia (238) · Netherlands (210) · Belgium (178) · Poland (178) · China (162) · Japan (147) · Czechia (134) · Denmark (121)
PMID 37870112, PMID 33175411, PMID 36602886, PMID 38588457, PMID 31072380, PMID 35305920, PMID 19775921, PMID 22900785, PMID 25918556, PMID 27657681, PMID 28403842, PMID 31401903, PMID 33974419, PMID 34532852, PMID 35164991, PMID 39800465, PMID 21762873, PMID 22163120, PMID 24144944, PMID 31353964, PMID 31356217, PMID 32107748, PMID 32593547, PMID 32956407, PMID 33189083, PMID 36463457, PMID 37059702, PMID 37148485, PMID 38114596, PMID 38706271, PMID 39688178, PMID 40368603, PMID 40680102, PMID 41114449, PMID 42613652, PMID 11112243, PMID 16135345, PMID 16275600, PMID 16763896, PMID 17175134, PMID 17941858, PMID 18296121, PMID 18619874, PMID 18662331, PMID 19453963, PMID 20548058, PMID 21300053, PMID 21484867, PMID 21586746, PMID 21594724
2014 (47), 2017 (36), 2009 (35), 2015 (35), 2016 (29), 2018 (26), 2019 (25), 2008 (19), 2023 (17), 2004 (11), U10CA098543 (11), U10CA180886 (11), 2005 (9), P30CA008748 (8), U01CA062399 (8)